Affiliation:
1. National Research Center for Therapy and Preventive Medicine
Abstract
Aim. To determine whether the Systematic Coronary Risk Evaluation (SCORE) level corresponds to the coronary artery calcium (CAC) score (Agatston score).Material and methods. The study included 212 people aged 40-65 years (mean age, 56,5±7,9 years). The number of men and women was 54 (25,5%) and 158 (74,5%), respectively.Results. According to the SCORE, the groups were distributed as follows: 62 (29,2%) — low risk, 128 (60,4%) — moderate risk, 16 (7,5%) — high risk, 6 (2,8%) — very high risk. The average SCORE level for the general group was 2,5±2,4%. According to the Agatston score, the groups were distributed as follows: minimal risk (0-10) — 142 (67%) people, low risk (11-100) — 42 (19,8%) people, moderate risk (101-400) — 17 (8%) people, high risk (≥401) — 7 (3,3%) people. Inconsistencies for all categories of cardiovascular risk were revealed between SCORE and Agatston score.Conclusion. The identified inconsistencies in the distribution of risk groups in accordance with the SCORE and Agatston score indicate that the SCORE scale is insufficiently informative. Multislice computed tomography coronary angiography with CAC calculation is additionally recommended, which will allow determining patient management and deciding on therapy. A comparative analysis of CAC score and the SCORE scale can help optimize, first of all, drug therapy for patients with hypertension and lipid metabolism disorders.
Subject
Cardiology and Cardiovascular Medicine,Education
Reference21 articles.
1. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982-3021.
2. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics — 2022 update: a report from the American Heart Association. Circulation. 2022;145:e153-e639.
3. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52.
4. Prevention of chronic noncommunicable diseases in the Russian Federation. National Guideline 2022. Cardiovascular Therapy and Prevention. 2022;21(4):3235. (In Russ.) doi:10.15829/1728-88002022-335.
5. Urazalina SJ. Stratification of cardiovascular risk, current status of the problem. Russian medical J. 2012;18;(5):39-45. (In Russ.) doi:10.17816/rmj38091.